ArticleNeuro-ophthalmology (Aeolus Press)2026
Clinical Features and Management of Optic Neuritis in a Cohort of Patients with Combined Central and Peripheral Demyelination.
Article in Neuro-ophthalmology (Aeolus Press), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Optic neuritis in combined central and peripheral demyelination (CCPD ON) is mainly reported from Eastern countries, with limited knowledge of its characteristics in Africa. Patients meeting both the EAN/PNS (European Academy of Neurology/Peripheral Nerve Society) criteria for chronic inflammatory demyelinating polyneuropathy (CIDP) and clinical criteria for ON were described in this study which involved antibody screening (ganglioside, NF186, NF155), myelin co-culture screens, CSF analysis, nerve conduction studies, visual evoked potentials (VEPs), optical coherence tomography (OCT), MR imaging and treatment outcomes, based on international guidelines for ON, CIDP, and CCPD, with minor modifications. Twelve patients (12/122, 9.8%) were included in the study. Clinical examination, VEPs, OCT and visual fields were consistent with anterior visual pathway dysfunction and nerve conduction studies confirmed peripheral demyelination. None of the patients had clinical evidence of a retinitis or vitritis. Five (42%) had symmetrical white matter disease including the corpus callosum and retro lentiform limb of internal capsule and one had MS-like lesions. Five (42%) had asymmetrical optic nerve (orbital) enhancement, and 2 (16%) optic sheath enhancement. Two were positive for NF155 antibodies, one had serum and CSF IgG immunoreactivity against non-myelinating Schwann cells. Eleven (91%) were responsive to immunotherapy with good functional recovery as reflected by post treatment visual acuity and inflammatory neuropathy cause and treatment (INCAT) scores. Visual symptoms in CIDP should alert the clinician to underlying CCPD. Early escalation therapy, which may include B-cell depleting therapy, leads to significant recovery which highlights the importance of early diagnosis and prompt escalation therapy. Prospective studies, to identify novel shared peripheral and central myelin epitopes, will fill diagnostic gaps, perhaps even in idiopathic ON, ultimately resulting in bespoke therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.